All You Need to Know About Sanara MedTech (SMTI) Rating Upgrade to Buy

Core Viewpoint - Sanara MedTech Inc. (SMTI) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - For the fiscal year ending December 2024, Sanara MedTech is expected to earn -$1.42 per share, reflecting a change of -173.1% from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Sanara MedTech has increased by 30%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Sanara MedTech in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].